Background stories of how others approached and experienced their European Horizon funding trajectory.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for detailsProfessor Lieven Eeckhout’s main research interests include computer architecture and the hardware/software interface with a specific emphasis on performance evaluation and modeling, and dynamic resource management.
Professor Eeckhout is the recipient of a European Research Council (ERC) Starting grant, Advanced grant and three Proof of Concept grants. Two of his former PhD students founded in 2013 CoScale, a spin-off in data center monitoring, which was acquired by New Relic.